PALI

Healthcare Biotechnology

Palisade Bio, Inc.

$1.49

-0.04 -2.61% today

Price History

Not enough data

Key Stats

Market Cap

259.66M

Avg Volume

2.69M

P/E (TTM)

2.48

EPS

$0.60

52W High

$2.86

52W Low

$1.32

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.32

P/B Ratio

2.13

P/S Ratio

519.33

EV/EBITDA

-3.81

EV/Revenue

268.99

Margins

Gross Margin 100.0%

Operating Margin (2339.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(51.4%)

Return on Assets

(33.0%)

Liquidity & Leverage

Current Ratio

24.26

Quick Ratio

23.96

Total Cash

125.17M

Total Debt

About

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.